is a partner at Grette and heads the firm's department for IP and Technology. Felix's practice is within the area of commercial law – with a focus on IP law, including trade marks, patents, designs and copyrights – as well as marketing law. In 2016 he representing GlaxoSmithKline Consumer Healthcare (GSK), succeeding in lifting an advertising ban imposed by the Norwegian Medicines Agency upon the medicinal product Voltarol. On 3 August 2016, the Oslo Registrars Court granted the injunction, considering it likely that the decision was invalid. After handling the administrative appeal, the Ministry reached the same conclusion. GSK was awarded legal costs for both the preliminary injunction and for the appeal procedure. Felix is a member of the Norwegian Bar Association's Law Committee for intellectual property and marketing law.